Market Cap: $125.85B
BC
Bristol-Myers Squibb Company
BMY
NYSE (New York Stock Exchange)USD
Market Cap: $125.85B
Bristol-Myers Squibb Company ( BMY ) is at the forefront of transformative changes within the oncology sector, as the company seeks to redefine its legacy through innovative therapies and strategic pa…
Bristol-Myers Squibb Company (Ticker: BMY) undergoes a key reclassification across the Russell indexes, marking a transformative moment for the company. Moving to the Russell 1000 Defensive and Russel…
Bristol Myers Squibb Company (Ticker: BMY) is making significant strides in the field of multiple myeloma treatment with recent advancements in its clinical trials. The company announces positive resu…
BristolMyers Squibb Company (Ticker: BMY) advances its position in oncology with strategic collaborations and innovative drug development. Recently, the company enters a clinical trial collaboration w…
Bristol-Myers Squibb Company (Ticker: BMY) achieves a significant milestone in cancer treatment with the European Commission's approval of Opdivo in combination with AVD as a frontline regimen for adv…
Bristol Myers Squibb Company (Ticker: BMY) has unveiled groundbreaking findings from its Phase 3 SUCCESSOR-2 trial, showcasing the efficacy of mezigdomide in patients with relapsed or refractory multi…
Bristol Myers Squibb Company (Ticker: BMY) partners with Anthropic to enhance its operational efficiency using advanced AI technology. This collaboration marks a significant milestone as it employs Cl…
Bristol-Myers Squibb Company (Ticker: BMY) announces a groundbreaking collaboration with Hengrui Pharma aimed at developing a portfolio of 13 early-stage drug programs in oncology, hematology, and imm…
Bristol-Myers Squibb Faces Challenges in Drug Performance and Market Competition Bristol-Myers Squibb (BMY) navigates a tumultuous period marked by significant challenges affecting its core pharmaceut…
Bristol-Myers Squibb Strengthens Focus on AI Innovations in Drug Development Bristol-Myers Squibb (BMS) is increasingly emphasizing the integration of artificial intelligence (AI) in its drug discover…
BioNTech’s Commitment to Transformative Healthcare Solutions BioNTech continues to forge ahead in its mission to revolutionize healthcare with its innovative mRNA technology, particularly in the criti…
Growing Trends in Gene Therapy Investment Reflect Industry Optimism Recent financial maneuvers in the biotechnology sector indicate a significant bullish sentiment towards gene therapy companies, exem…
Bristol Myers Squibb's Breakthrough in Psoriatic Arthritis Treatment: Introducing Sotyktu Bristol Myers Squibb Company (BMY) achieves a major milestone with the U.S. approval of Sotyktu, an oral medic…
Bristol Myers Squibb's Strategic Adaptation in the Age of Artificial Intelligence In the rapidly evolving pharmaceutical landscape, companies like Bristol Myers Squibb (BMS) are increasingly recognizi…
Bristol-Myers Squibb Engages Industry Leaders in Annual Meeting to Shape Future Direction Bristol-Myers Squibb (BMY) recently convenes its annual meeting featuring influential global leaders, reflecti…
Bristol-Myers Squibb Advances Treatment for Alpha-Thalassemia with Reblozyl Study Bristol-Myers Squibb Company (BMY) announces promising topline results from a Phase 2 study evaluating Reblozyl (luspa…
Analyst Notes Highlight Strategic Uncertainty at Bristol Myers Squibb Pipeline, Patents and Pricing: The Central Debate Sixteen sell‑side analysts over the past three months deliver a wide range of vi…
White House unveils TrumpRx; Bristol Myers Squibb cuts HIV drug price Bristol Myers Squibb is among a group of drugmakers that the White House says are joining a new Trump administration initiative, T…
Pharma earnings in focus as Bristol Myers Squibb prepares for a packed results week Bristol Myers Squibb is heading into a busy corporate reporting period that industry watchers say will refocus atten…
Bristol Myers Squibb Strengthens Commitment to Innovation Through Extended Partnership with Syngene International Bristol Myers Squibb (BMS) announces a significant extension of its strategic partners…
Bristol Myers Squibb Expands Strategic Partnership with Syngene International Bristol Myers Squibb (BMS) recently announces the extension of its long-standing partnership with Syngene International, a…
Accountability in the Wake of Tragedy: Bristol Health & Rehab Center Explosion Raises Safety Concerns In a tragic incident at the Bristol Health & Rehab Center in Bristol Township, a worker named Muth…
M&A Surge Reshapes Biotech Landscape: A New Era for Pharma Companies The biopharmaceutical sector is undergoing a transformative phase driven by a surge in mergers and acquisitions (M&A). As companies…
AstraZeneca's Anifrolumab Trial Paves the Way for Autoimmune Innovations AstraZeneca Plc’s recent announcement of the successful Phase 3 TULIP-SC trial results for anifrolumab marks a pivotal developm…
Bristol-Myers Squibb: Anticipation Grows Amid Increased Investor Activity Bristol-Myers Squibb (BMS) is currently experiencing a notable surge in investor enthusiasm, particularly among those with sig…